LEGS: 2-POINT IMPROVEMENT IN IGA PN-S

This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.

BASELINE:
IGA PN-S 3 (moderate,
20-99 nodules) DRAG TO SEE
RESULTS WEEK 24:
IGA PN-S 1
(almost
clear, 1-5 nodules)

BASELINE:
IGA PN-S 3 (moderate,
20-99 nodules) WEEK 24:
IGA PN-S 1
(almost
clear, 1-5 nodules)

In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).¹

ARM: 2-POINT IMPROVEMENT IN IGA PN-S

This adult patient was an actual patient (not a clinical trial patient) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results. Individual results may vary.

BASELINE:

IGA PN-S 3 (moderate,

20-99 nodules) Click and drag
to see results WEEK 24:

IGA PN-S 1 (almost
clear, 1-5 nodules)

BASELINE:

IGA PN-S 3 (moderate,

20-99 nodules) WEEK 24:

IGA PN-S 1 (almost
clear, 1-5 nodules)

In clinical trials, a clinical responder was defined as a patient achieving IGA PN-S 0 or 1 (the equivalent of 0-5 nodules).¹